{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T07:16:44Z","timestamp":1780384604772,"version":"3.54.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","pathologyjournal.rcpa.edu.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.pathol.2023.11.009","type":"journal-article","created":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T10:05:03Z","timestamp":1705572303000},"page":"404-412","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Immunohistochemistry screening for TP53 mutation in myeloid neoplasms in AZF-fixed bone marrow biopsies"],"prefix":"10.1016","volume":"56","author":[{"given":"Guang","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Anderson Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyu","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelsey","family":"McIntyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7127-6889","authenticated-orcid":false,"given":"Amy K.","family":"Beckman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4741-0010","authenticated-orcid":false,"given":"Andrew C.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2235-9930","authenticated-orcid":false,"given":"Sophia L.","family":"Yohe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pathol.2023.11.009_bib1","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1002\/gcc.22796","article-title":"The role of TP53 in acute myeloid leukemia: challenges and opportunities","volume":"58","author":"Barbosa","year":"2019","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.pathol.2023.11.009_bib2","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1002\/cncr.30203","article-title":"TP53 mutations in newly diagnosed acute myeloid leukemia: clinicomolecular characteristics, response to therapy, and outcomes","volume":"122","author":"Kadia","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.pathol.2023.11.009_bib3","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13045-015-0139-z","article-title":"TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases","volume":"8","author":"Ok","year":"2015","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.pathol.2023.11.009_bib4","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2023.11.009_bib5","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2023.11.009_bib6","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.beha.2019.05.004","article-title":"Current status and new treatment approaches in TP53 mutated AML","volume":"32","author":"Hunter","year":"2019","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.pathol.2023.11.009_bib7","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1200\/JCO.20.02342","article-title":"Eprenetapopt plus azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia: a phase II study by the Groupe Francophone des My\u00e9lodysplasies (GFM)","volume":"39","author":"Cluzeau","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2023.11.009_bib8","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.20.02341","article-title":"Eprenetapopt (APR-246) and azacitidine in TP53-mutant myelodysplastic syndromes","volume":"39","author":"Sallman","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2023.11.009_bib9","series-title":"Acute myeloid leukemia: NCCN evidence blocks. 2022","author":"National Comprehensive Cancer Network","year":"2023"},{"key":"10.1016\/j.pathol.2023.11.009_bib10","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/s41568-019-0202-0","article-title":"Nothing to gain for p53","volume":"19","author":"Harjes","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.pathol.2023.11.009_bib11","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/path.1838","article-title":"Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry","volume":"207","author":"Nenutil","year":"2005","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.pathol.2023.11.009_bib12","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood.2021013983","article-title":"TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia","volume":"140","author":"Tashakori","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2023.11.009_bib13","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/his.14726","article-title":"Correlation of p53 immunohistochemistry with TP53 mutational status and overall survival in newly diagnosed acute myeloid leukaemia","volume":"81","author":"Fitzpatrick","year":"2022","journal-title":"Histopathology"},{"key":"10.1016\/j.pathol.2023.11.009_bib14","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1002\/ajh.25255","article-title":"P53 protein overexpression in de novo acute myeloid leukemia patients with normal diploid karyotype correlates with FLT3 internal tandem duplication and worse relapse-free survival","volume":"93","author":"Assi","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.pathol.2023.11.009_bib15","first-page":"417","article-title":"Accuracy of bone marrow histochemical TP53 expression compared to the detection of TP53 somatic mutations in patients with myelodysplastic syndromes harbouring a del5q cytogenetic abnormality","volume":"11","author":"Oliva","year":"2021","journal-title":"Am J Blood Res"},{"key":"10.1016\/j.pathol.2023.11.009_bib16","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.3324\/haematol.2013.098103","article-title":"p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q)","volume":"99","author":"Saft","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.pathol.2023.11.009_bib17","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/modpathol.2014.153","article-title":"High p53 protein expression in therapy-related myeloid neoplasms is associated with adverse karyotype and poor outcome","volume":"28","author":"Cleven","year":"2015","journal-title":"Mod Pathol"},{"key":"10.1016\/j.pathol.2023.11.009_bib18","doi-asserted-by":"crossref","first-page":"e320","DOI":"10.3324\/haematol.2016.143214","article-title":"Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse clinical outcome in myelodysplastic syndromes and secondary acute myeloid leukemia","volume":"101","author":"McGraw","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.pathol.2023.11.009_bib19","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/modpathol.2016.206","article-title":"Immunohistochemistry for p53 is a useful tool to identify cases of acute myeloid leukemia with myelodysplasia-related changes that are TP53 mutated, have complex karyotype, and have poor prognosis","volume":"30","author":"Fernandez-Pol","year":"2017","journal-title":"Mod Pathol"},{"key":"10.1016\/j.pathol.2023.11.009_bib20","doi-asserted-by":"crossref","first-page":"e345","DOI":"10.3324\/haematol.2018.205302","article-title":"TP53 immunohistochemistry correlates with TP53 mutation status and clearance in decitabine-treated patients with myeloid malignancies","volume":"104","author":"Ruzinova","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.pathol.2023.11.009_bib21","doi-asserted-by":"crossref","first-page":"10","DOI":"10.14806\/ej.17.1.200","article-title":"Cutadapt removes adapter sequences from high-throughput sequencing reads","volume":"17","author":"Martin","year":"2011","journal-title":"EMBnet.journal"},{"key":"10.1016\/j.pathol.2023.11.009_bib22","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1471-2105-13-31","article-title":"PANDAseq: paired-end assembler for illumina sequences","volume":"13","author":"Masella","year":"2012","journal-title":"BMC Bioinform"},{"key":"10.1016\/j.pathol.2023.11.009_bib23","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","article-title":"Fast and accurate short read alignment with Burrows-Wheeler transform","volume":"25","author":"Li","year":"2009","journal-title":"Bioinformatics"},{"key":"10.1016\/j.pathol.2023.11.009_bib24","article-title":"Haplotype-based variant detection from short read sequencing","author":"Garrison","year":"2012","journal-title":"arXiv"},{"key":"10.1016\/j.pathol.2023.11.009_bib25","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1111\/ijlh.13088","article-title":"Characterization of myeloid malignancies with TP53 mutations and comparison to P53 expression by immunohistochemical staining methods","volume":"42","author":"Karner","year":"2020","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.pathol.2023.11.009_bib26","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s12308-020-00431-7","article-title":"p53 immunohistochemistry discriminates between pure erythroid leukemia and reactive erythroid hyperplasia","volume":"14","author":"Alexandres","year":"2021","journal-title":"J\u00a0Hematopathol"},{"key":"10.1016\/j.pathol.2023.11.009_bib27","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.3324\/haematol.2021.280487","article-title":"Pure erythroid leukemia is characterized by biallelic TP53 inactivation and abnormal p53 expression patterns in de novo and secondary cases","volume":"107","author":"Fang","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.pathol.2023.11.009_bib28","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/s41588-018-0204-y","article-title":"Mutational processes shape the landscape of TP53 mutations in human cancer","volume":"50","author":"Giacomelli","year":"2018","journal-title":"Nat Genet"},{"key":"10.1016\/j.pathol.2023.11.009_bib29","doi-asserted-by":"crossref","first-page":"a001107","DOI":"10.1101\/cshperspect.a001107","article-title":"Mutant p53 gain-of-function in cancer","volume":"2","author":"Oren","year":"2010","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.pathol.2023.11.009_bib30","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/cdd.2017.180","article-title":"Why are there hotspot mutations in the TP53 gene in human cancers?","volume":"25","author":"Baugh","year":"2018","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.pathol.2023.11.009_bib31","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1006\/jmbi.1995.0202","article-title":"Characterisation of epitopes on human p53 using phage-displayed peptide libraries: insights into antibody-peptide interactions","volume":"248","author":"Stephen","year":"1995","journal-title":"J\u00a0Mol Biol"},{"key":"10.1016\/j.pathol.2023.11.009_bib32","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/bpa.12173","article-title":"Revisiting TP53 mutations and immunohistochemistry--a comparative study in 157 diffuse gliomas","volume":"25","author":"Takami","year":"2015","journal-title":"Brain Pathol"},{"key":"10.1016\/j.pathol.2023.11.009_bib33","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.jpedsurg.2014.03.006","article-title":"Adrenocortical tumors in Italian children: analysis of clinical characteristics and P53 status. Data from the national registries","volume":"49","author":"Dall'Igna","year":"2014","journal-title":"J\u00a0Pediatr Surg"},{"key":"10.1016\/j.pathol.2023.11.009_bib34","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1016\/j.celrep.2019.08.061","article-title":"Integrated analysis of TP53 gene and pathway alterations in the Cancer Genome Atlas","volume":"28","author":"Donehower","year":"2019","journal-title":"Cell Rep"},{"key":"10.1016\/j.pathol.2023.11.009_bib35","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/petr.12585","article-title":"Increased p53 protein expression as a potential predictor of early relapse after hematopoietic stem cell transplantation in children with acute myelogenous leukemia","volume":"19","author":"Mattsson","year":"2015","journal-title":"Pediatr Transplant"}],"container-title":["Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302524000291?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302524000291?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T21:14:33Z","timestamp":1710450873000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031302524000291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0031302524000291"],"URL":"https:\/\/doi.org\/10.1016\/j.pathol.2023.11.009","relation":{},"ISSN":["0031-3025"],"issn-type":[{"value":"0031-3025","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunohistochemistry screening for TP53 mutation in myeloid neoplasms in AZF-fixed bone marrow biopsies","name":"articletitle","label":"Article Title"},{"value":"Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pathol.2023.11.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}